Nu-Med Plus (NUMD) Cash from Operations Growth (3y) (2015 - 2025)
Nu-Med Plus (NUMD) Cash from Operations Growth (3y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 20.35% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | -48.14% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 0.50% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 50.11% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | -14.75% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 15.83% |
| 10 | Nu-Med Plus | - | - | - | -12.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -12.79% |
| Sep 30, 2025 | -172.24% |
| Dec 31, 2024 | 56.43% |
| Jun 30, 2024 | 67.34% |
| Mar 31, 2024 | 82.16% |
| Dec 31, 2023 | 60.83% |
| Sep 30, 2023 | 42.84% |
| Jun 30, 2023 | 46.10% |
| Mar 31, 2023 | 40.39% |
| Dec 31, 2022 | 41.91% |
| Sep 30, 2022 | 26.17% |
| Jun 30, 2022 | 72.39% |
| Mar 31, 2022 | 63.36% |
| Dec 31, 2021 | 47.99% |
| Sep 30, 2021 | 34.05% |
| Jun 30, 2021 | 12.61% |
| Mar 31, 2021 | 1.04% |
| Dec 31, 2020 | 20.00% |
| Sep 30, 2020 | 7.55% |
| Jun 30, 2020 | -18.03% |